Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
EpiCept Corporation Announces Year End Results and Updates On Clinical Trials Surrounding Cancer Treatment
EpiCept Corporation recently announced operating and financial results for the year 2010, and provided an update on its key business initiatives.
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.